CGTX - cogrx.com Debt to Book Capitalization Ratio

Brandmark of Cognition Therapeutics (CGTX)

Cognition Therapeutics (CGTX) develops agents to preserve brain synapses, ensuring steady demand for its patents. The logistics network provides careful transportation of biomaterials, supporting the profitability of its developments. However, the lack of commercial products and negative cash flow make the business dependent on external capital, which amounts to 0.02. The stock's price chart is presented below.

cogrx.com (CGTX) - Debts to Book Value from 07/04/2022 to 10/28/2026
Flagship merchandise of cogrx.com

Complex pharmaceutical logistics for biosamples require significant capital expenditures from Cognition Therapeutics (CGTX), making capital structure control critically important. By analyzing the share of financial debt in the firm's balance sheet capitalization, an investor assesses the ratio of all borrowed obligations to the net asset value, determining the degree of financial stability and the risks of business dependence on external creditors.

Competitors of Cognition Therapeutics

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|Debts to Book Capitalization VKTX|Debt to Book Value SUPN|Catalyst Pharmaceuticals, Inc. - Debt to Book Capitalization Ratio|Debts to Book Value Denali (DNLI)|HRMY (Harmony Pharma) - Debts to Book Capitalization|Biohaven Corp - Debt to Net Assets|Amylyx Pharmaceuticals (AMLX) - Debt to Book Capitalization Ratio|TRVI - Debt to Book Value Ratio|Praxis Precision Medicines, Inc. - Debts to Book Capitalization|Debts to Net Assets Anavex|CeriBell Corp (CBLL) - Debt to Book Value|Debt to Book Capital prothena.com|ALEC (Alector, Inc.) - Debts to Book Capitalization|Debts to Net Assets ANNX (annexonbio.com)|OMER: Debt to Book Capitalization Ratio|Neurogene Inc - Debts to Book Value|AC Immune Corp (ACIU) - Debt to Book Capitalization Ratio|Voyager Corp (VYGR) - Debt to Book Value Ratio|Debt to Book Value Neumora Therapeutics NMRA|Debt to Net Assets Ratio scilexholding.com|Tevogen Bio (TVGN) - Debt to Book Value|Debt to Book Capital Alpha Cognition Corp|Inhibikase (IKT) - Debts to Book Capitalization|Debt to Net Assets Ratio Cassava Pharma (SAVA)|ASRT: Debts to Book Capitalization|Coya Therapeutics Inc - Debts to Book Value|Debt to Book Capitalization Ratio VistaGen Therapeutics Inc (VTGN)|OVID - Debt to Net Assets Ratio|ABOS: Debts to Book Capitalization|CRVO (CervoMed Corporation) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Alterity Therapeutics Ltd. ATHE|Debts to Book Capitalization Ratio Clene Nanomedicine|PepGen Inc. - Debts to Book Capitalization|Debts to Book Value Jupiter Neurosciences, Inc. JUNS|Debt to Book Value RLMD (Relmada)|ANVS - Debts to Book Capitalization|Debt to Book Value Grace Tx GRCE|AIFF - Debt to Book Capital|anewmeds.com - Debts to Book Capitalization|NeuroSense Therapeutics Ltd. (NRSN) - Debts to Net Assets|Debts to Book Capitalization RVPH|Debt to Book Value MTVA|NRXS (NeurAxis, Inc.) - Debt to Book Capitalization Ratio|Debts to Net Assets heliusmedical.com (HSDT)|Passage Bio - Debts to Book Capitalization|Debt to Book Value Neuphoria Therapeutics, Inc. NEUP|Debts to Book Capitalization NERV|Athira Pharma Corp (ATHA) - Debt to Net Assets|ADXN - Debt to Book Value|Debt to Book Capital Alzamend Neuro|Debt to Book Value Cyclerion Therapeutics Inc. (CYCN)|Debt to Book Value Ratio PTIX|Debt to Book Capitalization Ratio Pasithea Therapeutics KTTA|Debt to Book Value Ratio cortigent.com (CRGT)|ATXI: Debts to Book Capitalization|BCLI - Debts to Book Value|Cara Therapeutics - Debt to Book Value|CHRO: Debts to Book Capitalization|Debt to Book Capitalization Ratio eliemtx.com ELYM|ITCI (Intra-Cellular Therapies, Inc.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio LBPH (Longboard Pharmaceuticals)|Debts to Book Value marinuspharma.com|Debts to Book Capitalization NKGN (NKGen Biotech)|Debt to Book Value NRBO (NeuroBo Pharmaceuticals Inc)|SAGE: Debt to Book Capitalization Ratio|Debts to Book Value Synaptogenix, Inc SNPX|Debts to Book Capitalization TRVN|VIGL: Debt to Net Assets|Debt to Book Capitalization Ratio Anew Medical|Cerevel Therapeutics Inc (CERE) - Debt to Book Value Ratio